Table 2.
Case | Ø target size (mm) | FNAB cytology[1] | Location[2] | PTH-FNAB (ng/L) | Tg-FNAB (μg/L) |
Group 1 | |||||
1 | 22 | Thy 1 | L, I | 260 | >2500 |
2 | 18 | Thy 1 | L | 5 | 747 |
3 | 12 | Thy 1 | L | >2000 | >2500 |
4 | 8 | Thy 1 | R, I | >2000 | >2500 |
5 | 19 | Thy 1 | L | >2000 | >2500 |
6 | 21 | HP | R, I | 1854 | |
7 | 12 | HP | L, S | >2000 | >2500 |
8[3] | 15 | Thy 1 | R, S | 2 | 3 |
9 | 18 | HP | R, I | >2000 | >2500 |
10 | 10 | Thy 1 | L, I | 23 | 36 |
Group 2 | |||||
1 | 31 | Thy 2 | R, I, C | >2000 | >2500 |
2 | 10 | Thy 2 | R, S | <2 | |
3 | 18 | Thy 2 | L, I | 4 | >2500 |
4 | 24 | HP | R | >2000 | >2500 |
5 | 10 | Thy 5 | R | 6 | >2500 |
6 | 46 | FC | R, I | >2000 | >2500 |
7[4] | 16 | HP | L, I | 820 | 820 |
8[5] | 22 | Thy 1 | R, I, C | 156 | 3 |
9 | 17 | LN | L | 2 | 1097 |
10 | 12 | Thy 1 | L, I | >2000 | 199 |
11[6] | 15 | Thy 2 | L, I | >2000 | 274 |
12[7] | 11 | Thy 2 | R | 20 | >2500 |
13[8] | 9 | Thy 2 | R | 5 | >2500 |
14 | 24 | Thy 2 | L, I | >2000 | 466 |
15[9] | 16 | Thy 2 | L, I | 734 | 1 |
16 | 11 | Thy 2 | L | 12 | 1000 |
17 | 26 | Thy 2 | L | 2 | >2500 |
18 | 20 | Thy 3 | R, I | 33 | 274 |
19 | 22 | HP | R, I | >2000 | 54 |
20 | 8 | Thy 1 | R, I | 11 | 4 |
21 | 17 | HP | R, I | 1715 | 674 |
22 | 20 | Thy 2 | L, I | 5 | |
23[10] | 10 | Thy 2 | R, I | 2 | 799 |
24 | 11 | Thy 2 | L, I | 3 | 30 |
25 | 11 | Thy 2 | R, S | 14 | >2500 |
26 | 31 | Thy 2 | L | 7 | >2500 |
27 | 14 | Thy 1 | R, I | >2000 | |
28 | 30 | Thy 2 | R | 3 | 1839 |
29[11] | 12 | Thy 1 | L, I | 2 | >2500 |
30[12] | 21 | Thy 2 | L | 111 | 76 |
31[13] | 9 | Thy 2 | L | 2 | >2500 |
32 | 45 | Thy 2 | R | 2 | 370 |
33 | 16 | Thy 2 | R, I | 2 | 771 |
34 | 15 | Thy 1 | R, I | 1249 | 8 |
35[14] | 13 | Thy 2 | R | 3 | 431 |
36 | 22 | Thy 1 | R | >2000 | 652 |
37 | 28 | HP | R, C | >2000 | 2 |
Cytological diagnoses are reported according to the BTA when follicular cells were seen; the other cytological diagnoses were: HP: hyperplastic parathyroid cells; FC: fat cells; LN: lymph node cells.
Location (R: right side; L: left side; I: inferior; S: superior; C: cystic) of target is reported.
FNAB was not repeated owing to a concomitant disease diagnosed (prostatic cancer); hyperparathyroidism was considered to be secondary (creatinine 141.4 μmol/L).
FNAB was also performed on isthmic thyroid nodule (size 5 mm): PTH-FNAB 15 ng/L; Tg-FNAB >2500 μg/L; Thy 2.
FNAB was also performed on R cystic thyroid nodule (size 12 mm): PTH-FNAB 27 ng/L; Tg-FNAB 1245 μg/L; Thy 1.
FNAB was also performed on R cystic thyroid nodule (size 13 mm): PTH-FNAB 2 ng/L; Tg-FNAB >2500 μg/L; Thy 1.
FNAB was also performed on isthmic thyroid nodule (size 22 mm): PTH-FNAB 27 ng/L; Tg-FNAB >2500 μg/L; Thy 2.
FNAB was also performed on L thyroid nodule (size 22 mm): PTH-FNAB 3 ng/L; Tg-FNAB >2500 μg/L; Thy 2.
FNAB was also performed on L thyroid nodule (size 5 mm): PTH-FNAB 2 ng/L; Tg-FNAB >2500 μg/L; Thy 2.
FNAB was also performed on L nodule (size 36 mm): PTH-FNAB 2 ng/L; Tg-FNAB 84 μg/L; Thy 2.
Patient lost to follow-up.
FNAB was also performed on R thyroid nodule (size 23 mm): PTH-FNAB 114 ng/L; Tg-FNAB >2500 μg/L; Thy 2.
FNAB was also performed on L thyroid nodule (size 14 mm): PTH-FNAB 2 ng/L; Tg-FNAB 2460 μg/L; Thy 1.
FNAB was also performed on L thyroid nodule (size 15 mm): PTH-FNAB 3 ng/L; Tg-FNAB 1475 μg/L; Thy 2